Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 PB Ratio is 6.04 as of Aug. 13, 2026, which is 4% below its 10-year median of 6.26. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 784 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 83.16% on this metric.
The historical rank and industry rank for Avience Biomedicals's PB Ratio or its related term are showing as below:
NSE:AVIENCE'
s PB Ratio Range Over the Past 10 Years
Min: 5.37 Med: 6.26 Max: 9.99
Current: 6.05
During the past 3 years, Avience Biomedicals's highest PB Ratio was 9.99. The lowest was 5.37. And the median was 6.26.
NSE:AVIENCE's PB Ratio is ranked worse than 83.16% of 784
companies
in the Medical Devices & Instruments industry
Industry Median: 2.11
vs NSE:AVIENCE: 6.05
During the past 12 months, Avience Biomedicals's average Book Value Per Share Growth Rate was 266.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Avience Biomedicals PB Ratio Related Terms
Avience Biomedicals PB Ratio Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals PB Ratio Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
PB Ratio
0.00
0.00
0.00
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
PB Ratio
0.00
0.00
0.00
NSE:AVIENCE vs ABT, SYK, MDT: PB Ratio Comparison
For the Medical Devices subindustry, Avience Biomedicals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Avience Biomedicals (NSE:AVIENCE) has a PB Ratio of 6.04 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avience Biomedicals and its competitors. This is near median its historical median of 6.26. Over the past decade, Avience Biomedicals' PB Ratio has ranged from 5.37 to 9.99. According to the industry distribution chart, Avience Biomedicals ranks #652 out of 784 companies in the Medical Devices & Instruments industry, placing it in the top 83.2%.
Is Avience Biomedicals' PB Ratio too high?
Avience Biomedicals' current PB Ratio of 6.04 is near median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 5.37 to a high of 9.99. The Medical Devices & Instruments industry median PB Ratio is 2.11. Avience Biomedicals' value of 6.04 is 186.3% above this industry median. Based on the distribution chart, Avience Biomedicals ranks #652 out of 784 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #652 out of 784 companies for PB Ratio. This places Avience Biomedicals in the lower half of its industry. The industry median PB Ratio is 2.11. Avience Biomedicals' value of 6.04 is 186.3% above this benchmark. Historically, Avience Biomedicals' own PB Ratio has ranged from 5.37 to 9.99 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 2.11, Avience Biomedicals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.11, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current PB Ratio of 6.04 is 186.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current PB Ratio is 6.04, which is near median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current PB Ratio of 6.04. The current PB Ratio is 6.04, which is near median its 10-year median of 6.26 and 186.3% above the Medical Devices & Instruments industry median of 2.11. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current PB Ratio is 6.04 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
